Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:10:40.129Z.
Calculation as of: 2026-10-06T17:10:40.129Z.
Quote observation: 2026-10-06T17:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$839.73M
Price/OCF Ratio
N/A
TTM Avg
10.75
3Y Avg
10.75
5Y Avg
10.75
Market Cap
$840.18M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$830.86M
Price/OCF Ratio
N/A
TTM Avg
185.06
3Y Avg
185.06
5Y Avg
185.06
Market Cap
$857.24M
Price/OCF Ratio
N/A
TTM Avg
57.31
3Y Avg
41.26
5Y Avg
28.10
Market Cap
$860.99M
Price/OCF Ratio
347.45
TTM Avg
359.32
3Y Avg
359.32
5Y Avg
359.32
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $835.64M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $833.62M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $839.73M | N/A | 10.75 | 10.75 | 10.75 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.18M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $830.86M | N/A | 185.06 | 185.06 | 185.06 |
| QuidelOrtho Corporation (QDEL)vs › | $857.24M | N/A | 57.31 | 41.26 | 28.10 |
| SL Science Holding Ltd (SLBT)vs › | $858.07M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $810.71M | N/A | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $860.99M | 347.45 | 359.32 | 359.32 | 359.32 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.49M | 10.88 | 9.59 | 13.93 | 222.48 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
